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•SYSTEMATIC REVIEW AND META-ANALYSIS•

Meta-analysis of the Efficacy and Safety of Adjunctive
Rosuvastatin for Dyslipidemia in Patients with Schizophrenia
Wei ZHENG, #1 Wei YANG, #2 Qing-E ZHANG, 3 Xin-Hu YANG, 1 Dong-Bin CAI, 4 Jin-Qing HU, 1
Gabor S. UNGVARI, 5 Chee H. NG, 6 Marc De HERT, 7 Yu-Ping NING, 1* Yu-Tao XIANG8*

Background: Metabolic syndrome in patients with schizophrenia is a major health concern. The efficacy and
safety of adjunctive rosuvastatin in treating dyslipidemia were controversial.
Aims: To assess the efficacy and safety of adjunctive rosuvastatin for dyslipidemia in patients with
schizophrenia.
Methods: We systematically searched for relevant controlled clinical trials from the following databases:
PubMed, PsycINFO, Cochrane Library, China Knowledge Network, WanFang Database and Chinese Biomedical
Database up to September 28, 2017. Standardized mean difference (SMD) and risk ratio (RR) along with their
95% confidence intervals (CIs) were calculated. The quality of the included studies was assessed using the
Cochrane risk of bias assessment tool. The GRADE (Grades of Recommendation, Assessment, Development,
and Evaluation) system recommendation grading method was used as the reference standard.
Results: Four studies (n=274) comparing rosuvastatin (n=138) and control (n=136) groups were identified
and analyzed. Adjunctive rosuvastatin showed greater efficacy than control group in low density lipoprotein
cholesterol (LDL-C) [4 trials, n=272, SMD: -1.31 (95%CI: -1.93, -0.70), I2=81%], total cholesterol (2 trials,
n=164, SMD: -2.00 (95%CI: -2.79, -1.21); I2=76%) and triglycerides (2 trials, n=164, SMD: -1.05 (95%CI: -1.38,
-0.72); I2=0%), but not in high density lipoprotein cholesterol (2 trials, n=164, SMD: 0.14 (95%CI: -0.16, 0.45);
I2=0%). After removing one study without randomization for LDL-C, significance remained [3 trials, n=172,
SMD:-1.07 (95%CI: -1.60, -0.53); I2=63%]. No significant group differences regarding body weight (3 trials,
n=208, SMD: -0.40 (95%CI:-1.29, 0.49); I2=89%), body mass index (2 trials, n=164, SMD: -0.34 (95%CI: -1.23,
0.56); I2=87%), waist circumference (3 trials, n=208, SMD: -0.43 (95%CI: -1.31, 0.46); I2=89%), and fasting
glucose (4 trials, n=272, SMD: -0.25 (95%CI: -0.65, 0.15); I2=62%) were observed. The adverse reactions and
any cause discontinuation rate were similar between the groups. According to the GRADE approach, the
evidence levels of main outcomes were rated as ‘‘very low’’ (35.3%) to ‘‘low’’ (64.7%). Of them, the primary
outcome (LDL-C) was rated as “very low “.
Conclusions: The data available on the effectiveness and safety of adjunctive rosuvastatin in treating
dyslipidemia for patients with schizophrenia is insufficient to come to a definitive interpretation about its
efficacy and safety. Further high quality RCTs with extended treatment duration are warranted to confirm the
findings.
Review registration: PROSPERO: CRD42017078230
Key words: schizophrenia; rosuvastatin; dyslipidemia; low density lipoprotein cholesterol; meta-analysis
[Shanghai Arch Psychiatry. 2018; 30(1): 4-11. doi: http://dx.doi.org/10.11919/j.issn.1002-0829.217156]
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1. Introduction
Metabolic syndrome is an independent risk factor of
cardiovascular disease (CVD) [1,2] that is associated with
high treatment costs, risk of disability [3] and premature
death in schizophrenia patients. [4] A recent metaanalysis found that the pooled prevalence of metabolic
syndrome in patients with major psychiatric disorder
was 32.6%, with higher rates in schizophrenia (33.4%)
than bipolar disorder (31.7%) and major depression
(31.3%). [5] Of the metabolic syndrome features,
dyslipidemia, especially elevated low density lipoprotein
cholesterol (LDL-C), is a major cause of CVD.[6-8] Thus,
LDL-C lowering therapy could significantly reduce
the risk of CVD.[9]
Pharmacological and non-pharmacological
treatments have been widely used for metabolic
syndrome in schizophrenia. Of the pharmacotherapies,
statins appeared to be the most effective in reducing
the risk of ASCVD (atherosclerotic cardiovascular
disease) by decreasing the biosynthesis of
cholesterol.[7] As lipid-lowering drugs, statins mainly
played a role in LDL-C subfraction. [10] A cohort
study[8] found statins proved effective in improving
dyslipidaemia in schizophrenia patients. Of them,
rosuvastatin showed a large effect size in the
management of dyslipidemia.[11] Several controlled
studies [6,12-14] have found that rosuvastatin is effective
and safe in improving dyslipidemia in schizophrenia
patients although the findings have been inconsistent.
To the best of our knowledge, no systematic review
or meta-analyses of adjunctive rosuvastatin in treating
dyslipidemia in patients with schizophrenia have been
published. We thus conducted this meta-analysis of
controlled studies to examine the efficacy and safety of
adjunctive rosuvastatin for dyslipidemia in schizophrenia
patients.
2. Methods
2.1 Search Strategy and Selection Criteria
According to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement [15], English (PubMed, PsycINFO, and Cochrane
Library) and Chinese (China Knowledge Network,
WanFang Database and Chinese Biomedical Database)
databases were systematically searched by two authors
(WZ and D-BC) independently from their inception
up to September 28, 2017 using the following search
terms: (crestor OR rosuvastatin) AND (schizophrenic
disorder OR disorder, schizophrenic OR schizophrenic
disorders OR schizophrenia OR dementia praecox).
Moreover, the references of the included studies and
relevant reviews were also hand-searched for identifying
any omitted trials.
Two authors (WZ and D-BC) independently
assessed the eligibility of studies following the criteria
of the PICOS acronym. Participants: adult patients
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with schizophrenia according to any diagnostic
criteria. Intervention: rosuvastatin plus antipsychotics.
C o m p a r i s o n : a nt i p syc h o t i c s p l u s p l a c e b o o r
antipsychotics monotherapy. Outcomes: The primary
outcome measure was LDL-C (mg/dL). Secondary
outcomes were total cholesterol (mg/dL), high density
lipoprotein cholesterol (HDL-C, mg/dL), triglycerides
(mg/dL), fasting glucose (mg/dL), body weight (kg),
body mass index (BMI, kg/m2), waist circumference
(cm), improvement of psychotic symptoms as
assessed by the Positive and Negative Syndrome Scale
(PANSS) [16] or Brief Psychiatric Rating Scale (BPRS) [17],
discontinuation due to any reasons and adverse drug
reactions (ADRs). Study design: controlled studies
with meta-analyzable data on the efficacy and safety
of adjunctive rosuvastatin in improving dyslipidemia
or other metabolic symptoms. Furthermore, the title
of this meta-analysis are slightly different from the
registered protocol; i.e., the registered title “rosuvastatin
for dyslipidemia in schizophrenia: a metaanalysis” was
revised to “meta-analysis of the efficacy and safety of
adjunctive rosuvastatin for dyslipidemia in patients with
schizophrenia”.
2.2 Data extraction
Data from the included studies were independently
extracted and checked by two reviewers (X-HY and
D-BC). When intention-to-treat (ITT) or modified ITT
and observed cases data were reported concurrently,
ITT or modified ITT data were preferred following the
methodology of the previous meta-analysis. [18] The
corresponding or first authors of the relevant studies
were contacted for any unpublished data if needed.
2.3 Statistical methods
This meta-analysis was conducted using the random
effects model of Review Manager software (version
5.3 for Windows) (http://tech.cochrane.org/revman/)
due to potential heterogeneity across studies.[19] For
continuous outcomes, standardized mean differences
(SMDs) with the estimated effect size (Hedges’ g) were
calculated. For dichotomous outcomes, risk ratio (RR)
with its 95% confidence intervals (CIs) was computed.
The heterogeneity between studies was investigated
by considering the I2 method alongside the chi-squared
statistics, with I-squared ≥ 50% or Chi-squared p
value < 0.1 as heterogeneity.[20] Moreover, a subgroup
analysis (Chinese versus non-Chinese participants) was
conducted. Finally, funnel plots and Egger’s test [21] were
used to explore potential publication bias. All analyses
were two tailed, with significance level set at 0.05.
2.4 Assessment of reporting biases
The methodological quality of included studies were
assessed using the Cochrane risk of bias [22] and Jadad
scale.[23] The grading of recommendations assessment,
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Figure 1. Flowchart of identification of studies
13 articles published before September 28, 2017 were identified from PubMed (n=1), PsycINFO (n=2), and
Cochrane Library (n=0), China Knowledge Network (n=3), WanFang Database (n=4) and Chinese Biomedical
Database (n=3) using the following search terms (in the title or abstract): (crestor OR rosuvastatin) AND
(schizophrenic disorder OR disorder, schizophrenic OR schizophrenic disorders OR schizophrenia OR dementia
praecox).
3 duplicate reports excluded
The titles of the 10 articles were screened
6 reports were excluded

The full text of 4 articles were screened
no report was excluded

4 articles were included in the synthesis

development, and evaluation (GRADE) system ranged
from “very low”, “low”, “moderate”, to “high” was
used to interpret the overall quality level of the main
outcomes of meta-analysis.[24,25]
3. Results
3.1 Results of the search
The initial literature search in English and Chinese
databases yielded 13 electronic records (Figure 1).
Duplication excluded 3 trials. Of the remaining 10 trials,
6 were determined to be irrelevant after review of the
titles and abstracts, and zero were removed on the basis
of full text review. In the end, 4 eligible studies [6,12-14]
were included in this meta-analysis.
3.2 Characteristics of included studies
The 4 studies (n=274, Table 1) included 3 randomized
controlled trials (RCTs) (n=174) and one controlled
study without randomization (n=100) that compared
adjunctive rosuvastatin (n=138) and control groups (n
= 136). The weighted mean age was 39.3 years (range
= 34.1 - 43.5 years), weighted mean percentage of
males was 65.7% (range= 56.5% - 78.0%), and weighted
mean illness duration was 12.0 years (range= 5.8 - 15.5

years). The weighted mean of treatment duration was
10.4 weeks (range= 8 -12 weeks) (Table 1). Three RCTs
were conducted in China (n=174), and one in Belgium
(n=100). The dosage of rosuvastatin ranged from 5 to 10
mg/day. The baseline antipsychotics included clozapine
(1 trial), olazapine or risperidone (1 trial), and mixed
antipsychotics (2 trials). For example, De Hert et al’s
study [6] included first-generation and second-generation
antipsychotics (amisulpride, clozapine, risperidone,
olanzapine, and quetiapine).
3.3 Study quality and GRADE assessment
In one study [6] subjects were not randomized; the
remaining 3 RCTs [12-14] included two RCTs with double
blinded design and one RCT [12] with open label design.
One RCT [13] described randomization methods (i.e. the
random number table), while selective reporting and
other sources of bias were rated as having unclear risk in
all RCTs (Supplemental Figure 1). In 3 RCTs, the weighted
mean Jadad scores were 3.4 (range=2-5, Table 1). The
quality of evidence for primary and secondary outcomes
as assessed by the GRADE approach ranged from ‘‘very
low’’ (35.3%) to ‘‘low’’ (64.7%) (Supplemental Table 1).
Of them, the primary outcome (LDL-C) was rated as “very
low”.
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Table 1. Study and patient characteristics of the included trials
Study
Number Randomized Trial
(country) of
controlled Duration
patientsa trial
(wks)
De Hert
C: 48
No
12
2006
I: 52
(Belgium)
Gao
C: 33
Yes
8
2014
I: 31
(China)

Diagnosis Diagnostic Illness severity Agea:
a
Setting criteria
/durationa
yrs
(range)
SCZ (80),
DSM-IV -ND
38.5
SzA (20);
-13.1 yrs
(ND)
Both
SCZ (64);
ICD-10 -57.7 (PANSS)
34.1
Inpatients
-11.2 yrs
(18-40)

Sexa: ROS:
Jadad
Male Dose (mg/d): score
(%) mean (range)
78.0 Ø=10 (FD)
NA

Jiang
2017
(China)

C: 32
I: 32

Yes

12

SCZ (64);
Inpatients

ICD-10

-52.5 (PANSS)
-15.5 yrs

43.5 62.5
(18-60)

Qu
2015
(China)

C: 23
I: 23

Yes

8

SCZ (46);
Inpatients

ND

-66.1 (PANSS)
-5.8 yrs

42.5 56.5 Ø=ND (5-10)
(31-64)

56.5 Ø=ND (5-10)
Ø=5 (FD)

2
5
3

a

Available data were extracted based on mean baseline value of each included trials.

Abbreviations: Both=inpatients and outpatients; C=control; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders 4th
edition; FD=fixed dosage; I=intervention; ICD-10=the 10th revision of the International Statistical Classification of Diseases and
Related Health Problems; NA=not applicable; ND=not description; PANSS=Positive and Negative Syndrome Scale; ROS=rosuvastatin;
SCZ=schizophrenia; SzA=schizoaffective disorder; wks=weeks; yrs=years; Ø=mean.

3.4 Efficacy and safety
3.4.1 Primary outcome
Rosuvastatin group was superior to the control group
regarding the effects on LDL-C [4 trials, n=272, SMD:
-1.31 (95%CI: -1.93, -0.70), p < 0.001; I2 = 81%, Figure
2]. The significance remained after excluding one study
without randomization [6] [3 trials, n=172, SMD:-1.07
(95% CI : -1.60, -0.53), p < 0.001; I2 = 63%]. The subgroup
analysis found more positive effects of rosuvastatin in
non-Chinese than Chinese studies ( p = 0.01). As only 4
trials were analyzed for primary outcomes, publication
bias of LDL-C could not be examined using funnel plot or
Egger’s test.[26]
3.4.2 Secondary outcomes
Rosuvastatin group was also superior to the control
group in terms of the effects on total cholesterol (2
trials, n=164, SMD: -2.00 (95%CI : -2.79, -1.21), P <
0.001; I2 =76%) and triglycerides (2 trials, n = 164, SMD:
-1.05 (95%CI :-1.38, -0.72), p < 0.001; I2 =0%), but not in
HDL-C (2 trials, n = 164, SMD: 0.14 (95%CI: -0.16, 0.45),
p = 0.36; I2 =0%) (Table 2).
No significant differences in body weight (3 trials,
n = 208, SMD: -0.40 (95%CI: -1.29, 0.49), p = 0.38; I2 =
89%), BMI (2 trials, n=164, SMD: -0.34 (95%CI : -1.23,
0.56), p = 0.46; I2 = 87%), waist circumference (3 trials,
n = 208, SMD: -0.43 (95%CI: -1.31, 0.46), p = 0.34; I2
=89%), and fasting glucose (4 trials, n = 272, SMD: -0.25
(95%CI: -0.65, 0.15), p = 0.23; I2 =62%) were found
between rosuvastatin and the control group (Table 2).
Three studies measured the improvement of
psychotic symptoms as assessed by the PANSS, but did
not find any group difference (3 trials, n = 172, SMD:
0.05 (95%CI: -0.25, 0.34), p = 0.77; I2 =0%, Table 2).

Meta-analyses of ADRs including dizziness, dry
mouth, insomnia, tachycardia, constipation, nausea/
vomiting and extrapyramidal symptoms (Table 2)
showed no significant differences between groups (p =
0.29 to 0.92). Discontinuation rates due to any reasons
(2 trials, n = 128, RR: 1.99 (95%CI: 0.36, 11.08), p = 0.43;
I2 =0%) were also similar between groups (Table 2).
4. Discussion
4.1 Main findings
To our knowledge, this is the first meta-analysis to
examine the efficacy and safety of rosuvastatin as an
adjunctive treatment for dyslipidemia in patients with
schizophrenia. We found that adjunctive rosuvastatin
could significantly improve LDL-C with “very low”
evidence level based on GRADE assessment, total
cholesterol, and triglycerides in schizophrenia patients
treated with antipsychotics, which is consistent with
previous findings.[27,28]
4.2 Limitations
The following limitations should be acknowledged. First,
a heterogeneous result regarding the primary outcome
was found. Second, 4 trials with 274 patients were
included, which limits more comprehensive analyses
(i.e. meta-regression analysis). Third, the dose-response
effect of rosuvastatin for dyslipidemia was not evaluated
since the dosage of rosuvastatin varied across all studies
(5 to 10 mg/day). Fourth, the data on categorical
metabolic syndrome was only reported in one trial.[6]
Fifth, this meta-analysis did not focus on RCTs only,
which could decrease the validity of the findings. Sixth,
long-term effects of adjunctive rosuvastatin beyond 12
weeks were not examined. The quality of the studies
included in this meta-analysis was relatively low (such
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Table 2. Secondary outcomes
Study (subjects)

SMD/RR (95%CI)

I2 (%)

P-value

Total cholesterol (mg/dL)

2 (164)

-2.00 (-2.79, -1.21)

76

<0.001

Triglycerides (mg/dL)

2 (164)

-1.05 (-1.38, -0.72)

0

<0.001

HDL-C (mg/dL)

2 (164)

0.14 (-0.16, 0.45)

0

0.36

Body weight (kg)

3 (208)

-0.40 (-1.29, 0.49)

89

0.38

Waist circumference (cm)

3 (208)

-0.43 (-1.31, 0.46)

89

0.34

BMI (kg/m2)

2 (164)

-0.34 (-1.23, 0.56)

87

0.46

Fasting glucose (mg/dL)

4 (272)

-0.25 (-0.65, 0.15)

62

0.23

Discontinuation due to any reason

2 (128)

1.99 (0.36, 11.08)

0

0.43

Total psychopathology

3 (172)

0.05 (-0.25, 0.34)

0

0.77

ADRs: Dizziness

2 (108)

0.54 (0.10, 2.97)

0

0.48

Dry mouth

2 (126)

0.87 (0.31, 2.43)

0

0.79

Insomnia

3 (172)

1.52 (0.44, 5.23)

0

0.51

Tachycardia

2 (108)

2.41 (0.37, 15.83)

0

0.36

Constipation

3 (172)

1.06 (0.33, 3.40)

0

0.92

Nausea/vomiting

3 (172)

1.23 (0.37, 4.06)

0

0.73

Extrapyramidal symptoms

2 (126)

0.37 (0.06, 2.33)

0

0.29

Variables

Abbreviations: ADRs=adverse drug reactions; BMI= body mass index; CI=confidence intervals; HDL-C= high density lipoprotein
cholesterol; RR=risk ratio; SMD=Standard mean difference.

as one study without randomization) and the quality
of evidence for primary outcome was rated as ‘‘low’’.
Finally, the efficacy and safety of other statins for
dyslipidemia in patients with schizophrenia need to be
examined.
4.3 Implications
Due to the unhealthy lifestyle, irregular diet and need
for long-term antipsychotics use in schizophrenia
patients, the prevention and treatment of
metabolic syndrome is a major challenge in clinical
practice.[1] Other medications, such as metformin [29] and
topiramate [30,31], have been shown to improve weight
gain or BMI, however, such effects were not observed
with rosuvastatin in this study.
Hanssens et al found statin treatment for
schizophrenia patients was well tolerated except from
one patient who suffered from abnormal liver enzymes
and high CK levels.[8] Similarly, rosuvastatin appeared to
be relatively safe and well-tolerated for schizophrenia
patients in this meta-analysis. Previous studies have
found that rosuvastatin is associated with increased risk
of myotoxicity, ranging from muscle pain without
CK elevation to renal failure [32], and hepatotoxicity,

ranging from asymptomatic transient elevations to liver
failure.[33] However, none of these side effects were
reported in the included studies with the exception of
one study [6] where a subject had abnormal liver enzyme.
5. Conclusion
The data available on the effectiveness and safety of
adjunctive rosuvastatin in treating dyslipidemia for
patients with schizophrenia is insufficient to obtain a
definitive interpretation about its efficacy and safety.
Further high quality RCTs with extended treatment
duration are warranted to confirm the findings.
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Figure 2. Adjunctive rosuvastatin for dyslipidemia in schizophrenia patients: forest plot for low density
lipoprotein cholesterol (mg/dL)

Rosuvastatin
Study or Subgroup Mean SD Total
De Hert 2006
88.865 24.88 52
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Gao 2014
104.36 42.52 32
Jiang 2017
117.5 14.69 23
Qu 2015

Control
Std. Mean Difference
Mean SD Total Weight IV, Random, 95% CI
150.396 35.687 48 26.1% -2.00 [-2.48, -1.52]
127.16 6.57 32 24.4% -1.63 [-2.21, -1.05]
143.01 46.38 32 25.5% -0.86 [-1.37, -0.34]
126.39 8.5 23 24.0% -0.73 [-1.33, -0.13]

135 100.0%
137
Total (95% CI)
Heterogeneity: Tau² = 0.32; Chi² = 15.47, df = 3 (P = 0.001); I² = 81%
Test for overall effect: Z = 4.18 (P < 0.0001)
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对精神分裂症患者血脂异常的瑞舒伐他汀辅助治疗的疗效与安全性的的 Meta 分析
郑伟，杨威，张庆娥，杨欣湖，蔡东滨，胡晋卿，Ungvari.GS，HN Chee，Hert MD，宁玉萍，项玉涛

背景：精神分裂症患者的代谢综合征是一个重要的健
康问题。瑞舒伐他汀对血脂异常的辅助性治疗的有效
性和安全性存在争议。
目的：评价瑞舒伐他汀对精神分裂症患者血脂异常的
辅助性治疗的有效性和安全性。
方法：我们从以下数据库中系统地检索了 2017 年 9 月
28 日以前相关的临床对照试验：PubMed、PsycINFO、
Cochrane 图书馆、中国知网、万方数据库、中国生物
医学文献数据库。我们计算了标准平均差（SMD）、
风险比（RR）及其 95% 的可信区间（CIs）。使用偏移
评估工具中的 Cochrane 风险评估来评价所纳入研究的
质量。并采用 GRADE 系统推荐的等级方法（推荐、评估、
发展、评价的等级）作为参照标准。
结 果： 确 认 和 分 析 了 4 项 比 较 瑞 舒 伐 他 汀 组（n=
138）和对照组（n = 136）的研究（n = 274）。瑞舒伐
他汀辅助治疗显示对低密度脂蛋白胆固醇（LDL-C） [ 4
项试验，n = 272，SMD：-1.31（95%CI：-1.93，- 0.70），
I2 = 81% ]、总胆固醇（2 项试验，n = 164，SMD：-2.00
（95%CI：-2.79，- 1.21）；I2 = 76%）、和甘油三酯（2
项试验，n = 164，SMD：-1.05（95%CI：-1.38，- 0.72）；
I2 = 0%）的疗效比对照组更有效，但对高密度脂蛋白

胆 固 醇（2 项 试 验，n = 164，SMD：0.14（95%CI：0.16，0.45）；I2 = 0%）的疗效没有显著差异。去除一
项没有随机试验的 LDL-C 研究之后，显著差异仍然存
在 [ 3 项试验，n = 172，SMD：-1.07（95%CI：-1.60，0.53）；I2 = 63% ]。体重（3 项试验，n = 208，SMD：0.40（95%CI：-1.29，0.49）；I2 = 89%）、身体质量指
数（2 项试验，n = 164，SMD：-0.34（95%CI：-1.23，0.56）
；
I2 = 87%）、 腰 围（3 项 试 验，n = 208，SMD：-0.43
（95%CI：-1.31，0.46）；I2 = 89%）、空腹血糖（4 项
试 验，n = 272，SMD：-0.25（95%CI：-0.65，0.15）；
I2 = 62%）方面组间没有显著的差异。两组之间的不良
反应及停药率相近。根据 GRADE 分级方法，主要结
果的证据水平低被评为 “ 非常低 ”（35.3%） 到 “ 低 ”
（64.7%）。其中，主要结果（LDL-C）被评为“非常低”。

结论：对精神分裂症患者血脂异常的瑞舒伐他汀辅助
性治疗的现有数据尚不足以对其有效性和安全性做出
明确的解释。需进一步针对高质量的延长治疗时间的
随机对照试验来验证该结论。
关键词：精神分裂症；瑞舒伐他汀；血脂异常；低密
度脂蛋白胆固醇；Meta 分析；
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